<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443414</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-CO-203</org_study_id>
    <nct_id>NCT03443414</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>Phase IIb, Randomized, Double Blind, Placebo Controlled, Dose Ranging Study to Assess the Effect of RPL554 in Patients With Moderate to Severe COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the effect of 4 weeks of twice daily treatment of four different doses
      of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo in patients with moderate to
      severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to
      one of the five treatment options.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RPL554 is a dual inhibitor of PDE3 and PDE4 which are known to have a role in modulating the
      inflammatory airway response in respiratory diseases, including COPD. PDE3 inhibitors act as
      bronchodilators whilst PDE4 inhibitors have anti-inflammatory properties and there is also
      evidence to suggest that combined inhibition of PDE3 and PDE4 can have additive or
      synergistic anti-inflammatory and bronchodilator effects. PDE4 inhibitors (administered
      orally) have, however been associated with unfavorable gastrointestinal side effects such as
      nausea, emesis, diarrhea, abdominal pain, loss of appetite and weight loss. Dual PDE3/PDE4
      inhibitors (administered by inhalation) have exhibited both bronchodilator and
      anti-inflammatory actions, with a more favorable side effect profile. It is plausible that
      increased efficacy with reduced side effects may be achievable with administration of a dual
      PDE3/4 inhibitor by the inhaled route compared to orally administered PDE3 or PDE4
      inhibitors.

      The purpose of this study is to investigate the dose response of RPL554 in patients with COPD
      over 4 weeks. This length of time should allow for study of the bronchodilator response,
      measured predominantly by the peak forced expiratory volume in one second (FEV1), and the
      anti-inflammatory response, as measured predominantly by trough FEV1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">February 7, 2018</completion_date>
  <primary_completion_date type="Actual">January 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The nebuliser cup will be obscured to prevent the Investigator or outcomes assessor so the contents are not visible to the Investigator our outcomes assessor. The visual appearance of the study medication will not be discussed with the subject</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4</measure>
    <time_frame>Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).</time_frame>
    <description>Spirometry assessments were used to assess pulmonary function including the forced expiratory volume in 1 second (FEV1). Peak FEV1 at Week 4 was defined as the maximum post-dose value among the 30 minutes, 1, 2 and 3 hour assessments collected at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. A mixed model for repeated measures (MMRM) was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.
The least squares (LS) mean change from baseline FEV1 to peak FEV1 (as measured over 3 hours) at Week 4 is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline FEV1 to Morning Trough FEV1 at Week 4</measure>
    <time_frame>Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).</time_frame>
    <description>Morning trough FEV1 was defined as the last pre-dose value at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.
The LS mean change from baseline FEV1 to morning trough FEV1 at Week 4 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline FEV1 to Average FEV1 (Over 12 Hours) at Day 1 and Week 4</measure>
    <time_frame>Baseline (pre-dose, Visit 2), up to 12 hours post-dose at Visit 2 (Day 1) and Visit 6 (Week 4).</time_frame>
    <description>Average FEV1 over 12 hours was defined as the area under the curve from 0 to 12 hours post-dose (AUC[0-12]) of the FEV1 values collected during the visit under analysis (Day 1 or Week 4), divided by the length of the time interval of interest (in hours). The AUC was calculated using the trapezoidal rule. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.
The LS mean change from baseline FEV1 to average FEV1 over 12 hours at Day 1 and at Week 4 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in COPD Symptoms Using the Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT-PRO) Scoring at Week 4</measure>
    <time_frame>Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).</time_frame>
    <description>Patients completed an electronic diary (e-diary) once daily which used the 14-item EXACT-PRO instrument to assess COPD symptoms. The EXACT-PRO instrument contains 11 respiratory symptom questions that comprise the derivative Evaluating Respiratory Symptoms (E-RS) instrument that was used to measure the effect of treatment with RPL554 on the severity of COPD symptoms overall. The E-RS tool contains 3 subscales to assess breathlessness, cough/sputum and chest symptoms. In addition to the subscale scores, a total score for the E-RS part was obtained. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. Baseline was the last non-missing assessment taken prior to investigational product start date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Breathlessness as Assessed Using the St George's Respiratory Questionnaire (SGRQ) at Week 4</measure>
    <time_frame>Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).</time_frame>
    <description>Patients completed the COPD specific SGRQ (SGRQ-C) consisting of 14 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicate a worse outcome. Baseline assessment was pre-dose at Visit 2. MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, patient as random effect. The LS mean change from baseline in the total, symptoms, activity and impact SGRQ-C scores are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to end of study (approximately 6 weeks)</time_frame>
    <description>The number of patients with TEAEs for each the following categories are presented: any TEAE, any drug-related TEAE, any severe TEAE, any serious TEAE, serious drug-related TEAE, any TEAE leading to drug interruption, any TEAE leading to drug discontinuation, and any TEAE leading to death.
All AEs which started after the first dose of investigational product.or started prior to first dose and worsened, based on the Investigator assessment of severity, on or after first dose were considered to be treatment-emergent.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>0.75 mg RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6 mg RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPL554 suspension</intervention_name>
    <description>A dual PDE3/PDE 4 inhibitor</description>
    <arm_group_label>0.75 mg RPL554</arm_group_label>
    <arm_group_label>1.5 mg RPL554</arm_group_label>
    <arm_group_label>3 mg RPL554</arm_group_label>
    <arm_group_label>6 mg RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide informed consent

          -  Male or female aged 40 to 75 years

          -  Meeting specified contraception requirements

          -  12-lead electrocardiogram with heart rate 50-90 beats per minute, QT interval
             corrected using Fridericia's formula (QTcF) ≤450 msec (males) or ≤470 msec (females),
             QRS interval ≤120 msec, PR interval ≤200 msec and no clinically significant
             abnormalities

          -  Capable of complying with all study restrictions and procedures, including ability to
             use the study nebulizer correctly.

          -  Body mass index (BMI) 18 to 35 kg/m2 and minimum weight 45 kg.

          -  COPD diagnosis with symptoms compatible with COPD for at least 1 year

          -  Clinically stable COPD in the previous 4 weeks

          -  Ability to perform acceptable and reproducible spirometry.

          -  Post-bronchodilator spirometry at screening must demonstrate FEV1/forced vital
             capacity (FVC) ratio of ≤0.70 and FEV1 must be ≥40 % to ≤80% of predicted normal

          -  Chest X-ray (posterior-anterior) at screening, or chest X-ray, magnetic resonance
             imaging (MRI) or computed tomography (CT) scan in the last 12 months, showing no
             abnormalities which are both clinically significant and unrelated to COPD.

          -  Meet the concomitant medication restrictions and be expected to do so for the rest of
             the study.

          -  Current and former smokers with a smoking history of ≥10 pack years.

          -  Capable of withdrawing long acting bronchodilators until the end of the treatment
             period, and short acting bronchodilators for 8 hours prior to administration of study
             medication.

        Exclusion Criteria:

          -  A history of life-threatening COPD including Intensive Care Unit admission and
             requiring intubation.

          -  COPD exacerbation requiring oral steroids in the previous 3 months

          -  A history of one or more hospitalizations for COPD in the previous 6 months

          -  Lower respiratory tract infection treated with antibiotics in the previous 3 months

          -  Evidence of cor pulmonale or clinically significant pulmonary hypertension.

          -  Patients with a current diagnosis of asthma, active tuberculosis, lung cancer,
             bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnea,
             known alpha-1 antitrypsin deficiency or other active pulmonary diseases.

          -  Previous lung resection or lung reduction surgery.

          -  Oral therapies for COPD (e.g. oral steroids, theophylline, and roflumilast) in the
             previous 3 months and throughout the study.

          -  Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to
             Visit 1) and remains stable during the trial.

          -  A history of, or reason to believe a subject has, drug or alcohol abuse in the
             previous 3 years.

          -  Received an experimental drug within 30 days or five half-lives of the first dose

          -  Prior exposure to RPL554.

          -  Women who are pregnant or breast-feeding.

          -  Patients with a history of current uncontrolled disease that the Investigator believes
             are clinically significant.

          -  myocardial infarction in the previous 6 month; congestive heart failure, a history of
             unstable or uncontrolled hypertension, or has been diagnosed with hypertension in last
             3 months.

          -  Use of oral beta blockers.

          -  Major surgery (requiring general anesthesia) in the previous 6 weeks, lack of full
             recovery from surgery at screening, or planned surgery through the end of the study.

          -  History of malignancy of any organ system within 5 years, with the exception of
             localized skin cancers (basal or squamous cell).

          -  Clinically significant abnormal values for safety laboratory tests

          -  Significant non-compliance in previous investigational studies or with prescribed
             medications.

          -  Requirement for oxygen therapy, even on an occasional basis.

          -  Known hypersensitivity to RPL554 or its excipients/components.

          -  Abnormal clinically significant 12 lead Holter findings,

          -  Any other reason that the Investigator considers makes the subject unsuitable to
             participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Singh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit (MEU)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic for pneumonology</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATPPD-Ruse EOOD</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fifth MHAT - Sofia EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT 'Lyulin', EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NMTH Tsar Boris III</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Alexandrovska' EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Sveta Anna' AD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Nov</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediTrial s.r.o.</name>
      <address>
        <city>Jindřichův Hradec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plicni stredisko Teplice</name>
      <address>
        <city>Teplice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aerzte fuer Lungen- und</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienpraxis Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie GmbH &amp; Co. KG</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Keller</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inamed GmbH</name>
      <address>
        <city>Gauting</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRI Pulmonary Research</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburger Institut fuer</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>POIS Leipzig GbR</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SALVUS UG Centre for Clinial Trials</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLB Gesundheitsforschung</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologie Odeonsplatz</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologische Praxis Pasing</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballenberger Freytag Wenisch</name>
      <address>
        <city>Neu Isenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Christian Schlenska</name>
      <address>
        <city>Peine</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CERMED</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLIMED Marek Klimkiewicz</name>
      <address>
        <city>Bychawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silmedic sp. z o.o.</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grazyna Pulka Specjalistyczny</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Alergologii</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Alergo-MEDSpecjalistyczna</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Network Sp z o o</name>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Centrum Medyczne</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Opieka</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Terapii Wspólczesnej</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Klin</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C Angisan S.R.L</name>
      <address>
        <city>Bragadiru</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C Clinica Pneumomedica S.R.L</name>
      <address>
        <city>Braşov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundatia Dr. Victor Babes</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Cl. Pneumoftiziologie</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul CldePneumoftiziologie</name>
      <address>
        <city>Constanţa</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul CldePneumoftiziologie</name>
      <address>
        <city>Iaşi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <results_first_submitted>January 28, 2019</results_first_submitted>
  <results_first_submitted_qc>June 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2019</results_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD, bronchodilation, FEV1</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03443414/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03443414/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>405 adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) were randomized into this double-blind, multicenter study, and 403 received study medication. Patients were recruited to 47 study centers in Bulgaria, Czech Republic, Germany, Poland, Romania and the United Kingdom.</recruitment_details>
      <pre_assignment_details>Patients with a clinical diagnosis of COPD as defined by the American Thoracic Society/European Respiratory Society guidelines with symptoms compatible with COPD for at least 1 year prior to screening, and with clinically stable symptoms in the 4 weeks prior to screening and randomization were screened for inclusion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RPL554 0.75 mg</title>
          <description>Patients were randomized to receive 0.75 milligrams (mg) RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>RPL554 1.5 mg</title>
          <description>Patients were randomized to receive 1.5 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="P3">
          <title>RPL554 3.0 mg</title>
          <description>Patients were randomized to receive 3.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>RPL554 6.0 mg</title>
          <description>Patients were randomized to receive 6.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Patients were randomized to receive placebo administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="76"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline population consists of all randomized patients.</population>
      <group_list>
        <group group_id="B1">
          <title>RPL554 0.75 mg</title>
          <description>Patients were randomized to receive 0.75 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>RPL554 1.5 mg</title>
          <description>Patients were randomized to receive 1.5 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>RPL554 3.0 mg</title>
          <description>Patients were randomized to receive 3.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>RPL554 6.0 mg</title>
          <description>Patients were randomized to receive 6.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Patients were randomized to receive placebo administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="82"/>
            <count group_id="B4" value="80"/>
            <count group_id="B5" value="80"/>
            <count group_id="B6" value="405"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.6" spread="7.05"/>
                    <measurement group_id="B2" value="63.4" spread="6.40"/>
                    <measurement group_id="B3" value="62.5" spread="6.51"/>
                    <measurement group_id="B4" value="62.9" spread="6.73"/>
                    <measurement group_id="B5" value="63.5" spread="6.44"/>
                    <measurement group_id="B6" value="63.2" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="405"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="405"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4</title>
        <description>Spirometry assessments were used to assess pulmonary function including the forced expiratory volume in 1 second (FEV1). Peak FEV1 at Week 4 was defined as the maximum post-dose value among the 30 minutes, 1, 2 and 3 hour assessments collected at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. A mixed model for repeated measures (MMRM) was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.
The least squares (LS) mean change from baseline FEV1 to peak FEV1 (as measured over 3 hours) at Week 4 is presented.</description>
        <time_frame>Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).</time_frame>
        <population>The full analysis set (FAS) consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the number of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
        <group_list>
          <group group_id="O1">
            <title>RPL554 0.75 mg</title>
            <description>Patients were randomized to receive 0.75 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>RPL554 1.5 mg</title>
            <description>Patients were randomized to receive 1.5 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>RPL554 3.0 mg</title>
            <description>Patients were randomized to receive 3.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>RPL554 6.0 mg</title>
            <description>Patients were randomized to receive 6.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4</title>
          <description>Spirometry assessments were used to assess pulmonary function including the forced expiratory volume in 1 second (FEV1). Peak FEV1 at Week 4 was defined as the maximum post-dose value among the 30 minutes, 1, 2 and 3 hour assessments collected at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. A mixed model for repeated measures (MMRM) was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.
The least squares (LS) mean change from baseline FEV1 to peak FEV1 (as measured over 3 hours) at Week 4 is presented.</description>
          <population>The full analysis set (FAS) consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the number of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.203" lower_limit="0.152" upper_limit="0.253"/>
                    <measurement group_id="O2" value="0.209" lower_limit="0.160" upper_limit="0.258"/>
                    <measurement group_id="O3" value="0.257" lower_limit="0.208" upper_limit="0.306"/>
                    <measurement group_id="O4" value="0.196" lower_limit="0.147" upper_limit="0.246"/>
                    <measurement group_id="O5" value="0.057" lower_limit="0.007" upper_limit="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 6.0 mg - Placebo).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.139</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.069</ci_lower_limit>
            <ci_upper_limit>0.210</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 3.0 mg - Placebo).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.200</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.131</ci_lower_limit>
            <ci_upper_limit>0.270</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 1.5 mg - Placebo).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.153</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>0.222</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 0.75 mg - Placebo).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.146</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.075</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline FEV1 to Morning Trough FEV1 at Week 4</title>
        <description>Morning trough FEV1 was defined as the last pre-dose value at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.
The LS mean change from baseline FEV1 to morning trough FEV1 at Week 4 is presented.</description>
        <time_frame>Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).</time_frame>
        <population>The FAS consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the number of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
        <group_list>
          <group group_id="O1">
            <title>RPL554 0.75 mg</title>
            <description>Patients were randomized to receive 0.75 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>RPL554 1.5 mg</title>
            <description>Patients were randomized to receive 1.5 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>RPL554 3.0 mg</title>
            <description>Patients were randomized to receive 3.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>RPL554 6.0 mg</title>
            <description>Patients were randomized to receive 6.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline FEV1 to Morning Trough FEV1 at Week 4</title>
          <description>Morning trough FEV1 was defined as the last pre-dose value at Visit 6. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.
The LS mean change from baseline FEV1 to morning trough FEV1 at Week 4 is presented.</description>
          <population>The FAS consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the number of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" lower_limit="-0.038" upper_limit="0.053"/>
                    <measurement group_id="O2" value="-0.019" lower_limit="-0.063" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.040" lower_limit="-0.003" upper_limit="0.084"/>
                    <measurement group_id="O4" value="-0.026" lower_limit="-0.071" upper_limit="0.018"/>
                    <measurement group_id="O5" value="-0.028" lower_limit="-0.072" upper_limit="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 6.0 mg - Placebo).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>=0.953</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.061</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 3.0 mg - Placebo).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>=0.032</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.068</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.130</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 1.5 mg - Placebo).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>=0.773</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.009</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.053</ci_lower_limit>
            <ci_upper_limit>0.072</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 0.75 mg - Placebo).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>=0.272</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.035</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.028</ci_lower_limit>
            <ci_upper_limit>0.099</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline FEV1 to Average FEV1 (Over 12 Hours) at Day 1 and Week 4</title>
        <description>Average FEV1 over 12 hours was defined as the area under the curve from 0 to 12 hours post-dose (AUC[0-12]) of the FEV1 values collected during the visit under analysis (Day 1 or Week 4), divided by the length of the time interval of interest (in hours). The AUC was calculated using the trapezoidal rule. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.
The LS mean change from baseline FEV1 to average FEV1 over 12 hours at Day 1 and at Week 4 is presented.</description>
        <time_frame>Baseline (pre-dose, Visit 2), up to 12 hours post-dose at Visit 2 (Day 1) and Visit 6 (Week 4).</time_frame>
        <population>The FAS consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the number of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
        <group_list>
          <group group_id="O1">
            <title>RPL554 0.75 mg</title>
            <description>Patients were randomized to receive 0.75 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>RPL554 1.5 mg</title>
            <description>Patients were randomized to receive 1.5 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>RPL554 3.0 mg</title>
            <description>Patients were randomized to receive 3.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>RPL554 6.0 mg</title>
            <description>Patients were randomized to receive 6.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline FEV1 to Average FEV1 (Over 12 Hours) at Day 1 and Week 4</title>
          <description>Average FEV1 over 12 hours was defined as the area under the curve from 0 to 12 hours post-dose (AUC[0-12]) of the FEV1 values collected during the visit under analysis (Day 1 or Week 4), divided by the length of the time interval of interest (in hours). The AUC was calculated using the trapezoidal rule. Baseline was defined as the FEV1 pre-dose assessment (-15 minutes) collected at Visit 2. MMRM was used to model the change from baseline FEV1 using baseline FEV1 as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect.
The LS mean change from baseline FEV1 to average FEV1 over 12 hours at Day 1 and at Week 4 is presented.</description>
          <population>The FAS consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the number of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="79"/>
                    <count group_id="O5" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.088" lower_limit="0.058" upper_limit="0.117"/>
                    <measurement group_id="O2" value="0.077" lower_limit="0.048" upper_limit="0.107"/>
                    <measurement group_id="O3" value="0.103" lower_limit="0.074" upper_limit="0.132"/>
                    <measurement group_id="O4" value="0.095" lower_limit="0.065" upper_limit="0.125"/>
                    <measurement group_id="O5" value="0.008" lower_limit="-0.022" upper_limit="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="79"/>
                    <count group_id="O5" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" lower_limit="-0.007" upper_limit="0.085"/>
                    <measurement group_id="O2" value="0.052" lower_limit="0.008" upper_limit="0.096"/>
                    <measurement group_id="O3" value="0.085" lower_limit="0.040" upper_limit="0.130"/>
                    <measurement group_id="O4" value="0.031" lower_limit="-0.014" upper_limit="0.076"/>
                    <measurement group_id="O5" value="-0.033" lower_limit="-0.079" upper_limit="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 6.0 mg - Placebo) at Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.087</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.129</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 3.0 mg - Placebo) at Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.095</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.053</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 1.5 mg - Placebo) at Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>=0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.070</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.112</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 0.75 mg - Placebo) at Day 1.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.080</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 6.0 mg - Placebo) at Week 4.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>=0.048</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.065</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.129</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 3.0 mg - Placebo) at Week 4.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>LS mean difference</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.119</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 1.5 mg - Placebo) at Week 4.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>=0.008</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.149</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Placebo-corrected treatment effect: LS mean difference (RPL554 0.75 mg - Placebo) at Week 4.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A fixed-sequence testing approach was used, starting with the highest dose versus placebo. If a statistically significant difference was found at the 2-sided alpha level of 5%, the testing proceeded to the next highest dose.</non_inferiority_desc>
            <p_value>=0.028</p_value>
            <method>MMRM</method>
            <param_type>LS mean difference</param_type>
            <param_value>0.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in COPD Symptoms Using the Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT-PRO) Scoring at Week 4</title>
        <description>Patients completed an electronic diary (e-diary) once daily which used the 14-item EXACT-PRO instrument to assess COPD symptoms. The EXACT-PRO instrument contains 11 respiratory symptom questions that comprise the derivative Evaluating Respiratory Symptoms (E-RS) instrument that was used to measure the effect of treatment with RPL554 on the severity of COPD symptoms overall. The E-RS tool contains 3 subscales to assess breathlessness, cough/sputum and chest symptoms. In addition to the subscale scores, a total score for the E-RS part was obtained. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. Baseline was the last non-missing assessment taken prior to investigational product start date.</description>
        <time_frame>Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).</time_frame>
        <population>The FAS consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the number of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
        <group_list>
          <group group_id="O1">
            <title>RPL554 0.75 mg</title>
            <description>Patients were randomized to receive 0.75 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>RPL554 1.5 mg</title>
            <description>Patients were randomized to receive 1.5 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>RPL554 3.0 mg</title>
            <description>Patients were randomized to receive 3.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>RPL554 6.0 mg</title>
            <description>Patients were randomized to receive 6.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in COPD Symptoms Using the Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome (EXACT-PRO) Scoring at Week 4</title>
          <description>Patients completed an electronic diary (e-diary) once daily which used the 14-item EXACT-PRO instrument to assess COPD symptoms. The EXACT-PRO instrument contains 11 respiratory symptom questions that comprise the derivative Evaluating Respiratory Symptoms (E-RS) instrument that was used to measure the effect of treatment with RPL554 on the severity of COPD symptoms overall. The E-RS tool contains 3 subscales to assess breathlessness, cough/sputum and chest symptoms. In addition to the subscale scores, a total score for the E-RS part was obtained. The raw totals for the E-RS score and for each of the subscales were converted to a scale range of 0 to 100 (least symptomatic to most symptomatic). MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, and patient as random effect. Baseline was the last non-missing assessment taken prior to investigational product start date.</description>
          <population>The FAS consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the number of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>E-RS Total Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" lower_limit="-2.00" upper_limit="-0.14"/>
                    <measurement group_id="O2" value="-1.26" lower_limit="-2.16" upper_limit="-0.35"/>
                    <measurement group_id="O3" value="-0.80" lower_limit="-1.69" upper_limit="0.10"/>
                    <measurement group_id="O4" value="-0.92" lower_limit="-1.81" upper_limit="-0.02"/>
                    <measurement group_id="O5" value="1.19" lower_limit="0.30" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-RS Breathlessness Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" lower_limit="-0.92" upper_limit="-0.01"/>
                    <measurement group_id="O2" value="-0.63" lower_limit="-1.07" upper_limit="-0.18"/>
                    <measurement group_id="O3" value="-0.48" lower_limit="-0.92" upper_limit="-0.04"/>
                    <measurement group_id="O4" value="-0.48" lower_limit="-0.92" upper_limit="-0.04"/>
                    <measurement group_id="O5" value="0.47" lower_limit="0.03" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-RS Cough/Sputum Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" lower_limit="-0.50" upper_limit="0.07"/>
                    <measurement group_id="O2" value="-0.30" lower_limit="-0.58" upper_limit="-0.03"/>
                    <measurement group_id="O3" value="-0.14" lower_limit="-0.41" upper_limit="0.13"/>
                    <measurement group_id="O4" value="-0.21" lower_limit="-0.48" upper_limit="0.06"/>
                    <measurement group_id="O5" value="0.36" lower_limit="0.09" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-RS Chest Symptoms Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" lower_limit="-0.70" upper_limit="-0.08"/>
                    <measurement group_id="O2" value="-0.32" lower_limit="-0.62" upper_limit="-0.02"/>
                    <measurement group_id="O3" value="-0.19" lower_limit="-0.48" upper_limit="0.11"/>
                    <measurement group_id="O4" value="-0.22" lower_limit="-0.52" upper_limit="0.07"/>
                    <measurement group_id="O5" value="0.35" lower_limit="0.05" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Breathlessness as Assessed Using the St George's Respiratory Questionnaire (SGRQ) at Week 4</title>
        <description>Patients completed the COPD specific SGRQ (SGRQ-C) consisting of 14 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicate a worse outcome. Baseline assessment was pre-dose at Visit 2. MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, patient as random effect. The LS mean change from baseline in the total, symptoms, activity and impact SGRQ-C scores are presented.</description>
        <time_frame>Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).</time_frame>
        <population>The FAS consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the numbers of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
        <group_list>
          <group group_id="O1">
            <title>RPL554 0.75 mg</title>
            <description>Patients were randomized to receive 0.75 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>RPL554 1.5 mg</title>
            <description>Patients were randomized to receive 1.5 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>RPL554 3.0 mg</title>
            <description>Patients were randomized to receive 3.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>RPL554 6.0 mg</title>
            <description>Patients were randomized to receive 6.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Breathlessness as Assessed Using the St George's Respiratory Questionnaire (SGRQ) at Week 4</title>
          <description>Patients completed the COPD specific SGRQ (SGRQ-C) consisting of 14 items each weighted from 0 to a possible maximum of 100. Items 1-7 produced the symptoms score, 9-12 the activity score, and items 8, 10, 11, 13 and 14 the impacts score. Each component sub-score was calculated as a percentage of the summed weights of each item out of the sum of the maximum possible weight for that component (range 0-100). The total score was calculated by summing the weights to all positive responses in each component, where a positive item indicated the presence of symptoms, expressed as a percentage (range 0-100). Higher scores indicate a worse outcome. Baseline assessment was pre-dose at Visit 2. MMRM was used to model the change from baseline using baseline as a continuous fixed effect, randomized treatment, week and treatment-by-week as categorical fixed effect, patient as random effect. The LS mean change from baseline in the total, symptoms, activity and impact SGRQ-C scores are presented.</description>
          <population>The FAS consisted of all randomized patients, who received at least 1 dose of investigational product during the study and with at least 1 post-treatment efficacy data assessment. Data is presented for the numbers of patients with at least 1 on-treatment value who contributed to the model estimate.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SGRQ-C Total score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" lower_limit="-5.13" upper_limit="0.02"/>
                    <measurement group_id="O2" value="-3.18" lower_limit="-5.72" upper_limit="-0.65"/>
                    <measurement group_id="O3" value="-2.63" lower_limit="-5.24" upper_limit="-0.01"/>
                    <measurement group_id="O4" value="-3.01" lower_limit="-5.51" upper_limit="-0.51"/>
                    <measurement group_id="O5" value="-0.33" lower_limit="-2.90" upper_limit="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SGRQ-C Symptoms score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.73" lower_limit="-7.99" upper_limit="-1.46"/>
                    <measurement group_id="O2" value="-1.89" lower_limit="-5.11" upper_limit="1.33"/>
                    <measurement group_id="O3" value="-2.17" lower_limit="-5.50" upper_limit="1.17"/>
                    <measurement group_id="O4" value="-4.33" lower_limit="-7.51" upper_limit="-1.16"/>
                    <measurement group_id="O5" value="1.25" lower_limit="-2.02" upper_limit="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SGRQ-C Activity score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" lower_limit="-5.30" upper_limit="0.91"/>
                    <measurement group_id="O2" value="-4.28" lower_limit="-7.34" upper_limit="-1.23"/>
                    <measurement group_id="O3" value="-2.70" lower_limit="-5.85" upper_limit="0.46"/>
                    <measurement group_id="O4" value="-2.75" lower_limit="-5.76" upper_limit="0.27"/>
                    <measurement group_id="O5" value="-2.16" lower_limit="-5.25" upper_limit="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SGRQ-C Impact score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="73"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" lower_limit="-4.91" upper_limit="1.46"/>
                    <measurement group_id="O2" value="-2.93" lower_limit="-6.06" upper_limit="0.20"/>
                    <measurement group_id="O3" value="-2.96" lower_limit="-6.20" upper_limit="0.28"/>
                    <measurement group_id="O4" value="-2.80" lower_limit="-5.89" upper_limit="0.29"/>
                    <measurement group_id="O5" value="0.11" lower_limit="-3.07" upper_limit="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>The number of patients with TEAEs for each the following categories are presented: any TEAE, any drug-related TEAE, any severe TEAE, any serious TEAE, serious drug-related TEAE, any TEAE leading to drug interruption, any TEAE leading to drug discontinuation, and any TEAE leading to death.
All AEs which started after the first dose of investigational product.or started prior to first dose and worsened, based on the Investigator assessment of severity, on or after first dose were considered to be treatment-emergent.</description>
        <time_frame>Up to end of study (approximately 6 weeks)</time_frame>
        <population>The safety analysis set consisted of all patients who received at least 1 dose of investigational product during the study.</population>
        <group_list>
          <group group_id="O1">
            <title>RPL554 0.75 mg</title>
            <description>Patients were randomized to receive 0.75 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>RPL554 1.5 mg</title>
            <description>Patients were randomized to receive 1.5 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>RPL554 3.0 mg</title>
            <description>Patients were randomized to receive 3.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>RPL554 6.0 mg</title>
            <description>Patients were randomized to receive 6.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Patients were randomized to receive placebo administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>The number of patients with TEAEs for each the following categories are presented: any TEAE, any drug-related TEAE, any severe TEAE, any serious TEAE, serious drug-related TEAE, any TEAE leading to drug interruption, any TEAE leading to drug discontinuation, and any TEAE leading to death.
All AEs which started after the first dose of investigational product.or started prior to first dose and worsened, based on the Investigator assessment of severity, on or after first dose were considered to be treatment-emergent.</description>
          <population>The safety analysis set consisted of all patients who received at least 1 dose of investigational product during the study.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to drug interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs were collected from the first dose of investigational product up to 2 weeks after the end of the study (Visit 6) (approximately 6 weeks).</time_frame>
      <desc>The safety analysis set consisted of all patients who received at least 1 dose of investigational product during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>RPL554 0.75 mg</title>
          <description>Patients were randomized to receive 0.75 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>RPL554 1.5 mg</title>
          <description>Patients were randomized to receive 1.5 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>RPL554 3.0 mg</title>
          <description>Patients were randomized to receive 3.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="E4">
          <title>RPL554 6.0 mg</title>
          <description>Patients were randomized to receive 6.0 mg RPL554 administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Patients were randomized to receive placebo administered by jet nebulizer twice daily (morning and evening) for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="82"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator and Institution may only publish their center study activities and/or study data with prior written approval of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Maurer, Senior Clinical Operations Director</name_or_title>
      <organization>Verona Pharma</organization>
      <phone>(914) 767-5037</phone>
      <email>brian.maurer@veronapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

